ABOS (Acumen Pharmaceuticals, Inc) Forward P/S Multiple
The forward P/S of Acumen Pharmaceuticals (ABOS) reflects the business valuation trend, where the value captures the metric level. A patent portfolio of monoclonal antibodies and steady demand for Alzheimer's therapy create potential for future cash flow. A strong team of neurobiologists is supported by generous R&D funding. However, the lack of commercial products leaves the company dependent on scientific breakthroughs without current operating profit.
Summary analytical data breakdowns for Acumen Pharmaceuticals, Inc (ABOS)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity Acumen Pharmaceuticals|ABOS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Acumen Pharmaceuticals|ABOS - Company Aggregate Debts|Debts to Book Capitalization Acumen Pharmaceuticals, Inc|ABOS - Company Long-Term Liabilities|Company Short-Term Debts Acumen Pharmaceuticals|Quick Liquidity Indicator acumenpharm.com
- financial results and valuation multiples details:
ABOS - Net Profit|Future Profit Acumen Pharmaceuticals|ABOS - Market Price to Net Income Ratio|Forward P/E Multiple Acumen Pharma|ABOS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Acumen Pharmaceuticals, Inc|ABOS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Acumen Pharmaceuticals|ABOS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months acumenpharm.com|ABOS - Earnings per share growth in current year|Net earnings per share growth forecast for next year Acumen Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:Acumen Pharmaceuticals, Inc. ABOS
To minimize risks during a long-term entry, it is essential to correlate market capitalization with projected revenue from 10-K/10-Q filings, which allows for the determination of asset overvaluation via the projected P/S trend. For Acumen Pharmaceuticals (ABOS), this indicator confirms fundamental stability, as exclusive antibody patents and high FDA barriers protect future cash flows from competition.
Competitors of Acumen Pharmaceuticals (ABOS)
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX (Neurocrine) - Future Price to Revenue|Regencell - Forward P/S Multiple|Forward Price to Sales AXSM (Axsome Corp)|ACAD: Forward P/S Multiple|xenon-pharma.com (XENE) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|SUPN: Forward Price to Sales|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Forward Price-to-Revenue Multiple Denali Corp DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Trevi Therapeutics Inc (TRVI) - Forward Price-to-Revenue Multiple|PRAX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Anavex Life Sciences Corp (AVXL)|Forward Price-to-Revenue Multiple CBLL|Forward P/S Multiple Prothena Corporation|Forward Price-to-Revenue Multiple ALEC (Alector, Inc.)|Price to Expected Revenue Ratio ANNX|Forward P/S Multiple OMER (Omeros)|Market Cap to Expected Sales Ratio Neurogene Therapeutics (NGNE)|AC Immune - Forward P/S Multiple|voyagertherapeutics.com (VYGR) - Forward Price-to-Revenue Multiple|NMRA: Forward P/S Multiple|Scilex Holding (SCLX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Price-to-Projected Revenue Ratio ACOG|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|Market Cap to Expected Sales Ratio inhibikase.com|Forward P/S Multiple SAVA (Cassava Sciences)|Forward P/S Multiple Assertio Holdings ASRT|Coya - Forward P/S Multiple|VTGN: Price-to-Projected Revenue Ratio|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio cervomed.com (CRVO)|Price-to-Projected Revenue Ratio Alterity Therapeutics Ltd.|Clene Nanomedicine (CLNN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Market Cap to Future Revenue Ratio|GRCE: Forward Price-to-Revenue Multiple|AIFF - Forward P/S Multiple|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|NeuroSense Therapeutics Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|Market Cap to Future Revenue Ratio MetaVia, Inc. MTVA|Forward P/S Multiple NRXS|Forward P/S Multiple heliusmedical.com (HSDT)|Forward P/S Multiple PASG (Passage Bio)|NEUP - Forward Price-to-Revenue Multiple|NERV: Forward Price-to-Revenue Multiple|ATHA - Forward P/S Multiple|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Alzamend Neuro|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Protagenic PTIX|Price-to-Projected Revenue Ratio Pasithea Therapeutics (KTTA)|cortigent.com - Market Cap to Projected Revenue|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales BCLI|CARA - Price-to-Projected Revenue Ratio|Future Price to Revenue CHRO|ELYM: Forward P/S Multiple|Intra-Cellular Therapies, Inc. - Forward Price to Sales|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Forward P/S Multiple Marinus Pharmaceuticals Inc|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO (NeuroBo Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX - Forward Price-to-Revenue Multiple|Trevena - Forward P/S Multiple|VIGL - Forward P/S Multiple|WENA: Forward P/S Multiple|Forward Price-to-Revenue Multiple Cerevel Corp
